Table 3 Efficacy of mobilization with plerixafor plus G-CSF

From: Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

  Myeloma Lymphoma All cases
PB CD34+ levels (cells per μL)
Before plerixafor
 Patients tested N (%) 17 (53) 13 (54) 30 (54)
 Median 4.9 3.3 3.6
 Min–Max 1.1–13.0 1.2–9.8 1.1–13.0
 Mean (s.d.) 4.5 (3.6) 3.9 (2.7) 4.2 (3.1)
After plerixafor
 Patients tested, N (%) 22 (69) 19 (79) 41 (73)
 Median 18.7 17.0 17.9
 Min–Max 2.8–192.0 2.9–35.9 2.8–192.2
 Mean (s.d.) 30.8 (41.9) 17.4 (9.7) 24.9 (32.4)
 Patients reaching 10 N (%) 16 (73) 13 (68) 29 (71)
Fold-increase with plerixafor
 Patients tested, N (%) 17 (53) 13 (54) 30 (54)
 Median 4.6 5.9 4.9
 Min–Max 0.6–38.4 1.5–13.3 0.6–38.4
 Mean (s.d.) 9.4 (12.1) 6.3 (3.8) 7.6 (8.3)
Apheresis procedures
 Median 2 2 2
 Min–Max 1–4 0–4 0–4
 Mean (s.d.) 2.0 (0.8) 1.75 (0.9) 1.9 (0.8)
CD34+ PBSCs collected ( × 10 6 per kg)
 Median 2.8 2.3 2.6
 Min–Max 0.4–10.6 1.1–4.6 0.4–10.6
 Mean (s.d.) 3.4 (2.1) 2.5 (0.9) 3.0 (1.7)
 Patients collecting 2 N (%) 27 (84) 15 (63) 42 (75)